Log in

NASDAQ:SLNO - Soleno Therapeutics Stock Price, Forecast & News

+0.14 (+4.33 %)
(As of 02/20/2020 02:59 AM ET)
Today's Range
Now: $3.37
50-Day Range
MA: $3.11
52-Week Range
Now: $3.37
Volume128,567 shs
Average Volume208,747 shs
Market Capitalization$150.50 million
P/E RatioN/A
Dividend YieldN/A
Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc and changed its name to Soleno Therapeutics, Inc in May 2017. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:SLNO



Sales & Book Value

Annual SalesN/A
Book Value$0.96 per share


Net Income$-13,340,000.00


Market Cap$150.50 million
Next Earnings Date3/16/2020 (Estimated)
OptionableNot Optionable

Receive SLNO News and Ratings via Email

Sign-up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.

Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?

Soleno Therapeutics's stock reverse split on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics Inc (NASDAQ:SLNO) issued its earnings results on Wednesday, August, 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.14. View Soleno Therapeutics' Earnings History.

When is Soleno Therapeutics' next earnings date?

Soleno Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Soleno Therapeutics.

What price target have analysts set for SLNO?

3 analysts have issued twelve-month target prices for Soleno Therapeutics' shares. Their forecasts range from $8.00 to $10.00. On average, they expect Soleno Therapeutics' share price to reach $9.33 in the next year. This suggests a possible upside of 177.0% from the stock's current price. View Analyst Price Targets for Soleno Therapeutics.

What is the consensus analysts' recommendation for Soleno Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soleno Therapeutics.

Has Soleno Therapeutics been receiving favorable news coverage?

Media stories about SLNO stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Soleno Therapeutics earned a news sentiment score of -4.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Soleno Therapeutics.

Are investors shorting Soleno Therapeutics?

Soleno Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 239,200 shares, a drop of 38.2% from the January 15th total of 387,000 shares. Based on an average daily volume of 287,900 shares, the short-interest ratio is currently 0.8 days. Approximately 0.8% of the company's stock are short sold. View Soleno Therapeutics' Current Options Chain.

Who are some of Soleno Therapeutics' key competitors?

What other stocks do shareholders of Soleno Therapeutics own?

Who are Soleno Therapeutics' key executives?

Soleno Therapeutics' management team includes the folowing people:
  • Dr. Anish Bhatnagar, Pres, CEO & Director (Age 49)
  • Mr. Anthony Wondka, Sr. VP of R&D (Age 57)
  • Mr. David D. O'Toole, Consultant (Age 60)
  • Mr. Jonathan R. Wolter, CFO & Principal Accounting Officer (Age 69)
  • Dr. Neil M. Cowen Ph.D., MBA, Sr. VP of Drug Devel.

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Abingworth LLP (15.61%), J. Goldman & Co LP (0.47%), Renaissance Technologies LLC (0.29%), Banco Bilbao Vizcaya Argentaria S.A. (0.11%), Shikiar Asset Management Inc. (0.08%) and Lindbrook Capital LLC (0.02%). Company insiders that own Soleno Therapeutics stock include Andrew Sinclair, Bioasia Mangement Llc, Gwen A Melincoff, Jack W Schuler, Larry N Feinberg, Technology Partners Fund Vii L, Ventures Fund V LP Vivo and Vivo Ventures V, Llc. View Institutional Ownership Trends for Soleno Therapeutics.

Which major investors are selling Soleno Therapeutics stock?

SLNO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have sold Soleno Therapeutics company stock in the last year include Bioasia Mangement Llc, Ventures Fund V LP Vivo and Vivo Ventures V, Llc. View Insider Buying and Selling for Soleno Therapeutics.

Which major investors are buying Soleno Therapeutics stock?

SLNO stock was purchased by a variety of institutional investors in the last quarter, including Abingworth LLP, J. Goldman & Co LP, Banco Bilbao Vizcaya Argentaria S.A., Lindbrook Capital LLC and Shikiar Asset Management Inc.. Company insiders that have bought Soleno Therapeutics stock in the last two years include Andrew Sinclair, Gwen A Melincoff, Jack W Schuler and Larry N Feinberg. View Insider Buying and Selling for Soleno Therapeutics.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $3.37.

How big of a company is Soleno Therapeutics?

Soleno Therapeutics has a market capitalization of $150.50 million. The company earns $-13,340,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Soleno Therapeutics employs 9 workers across the globe.View Additional Information About Soleno Therapeutics.

What is Soleno Therapeutics' official website?

The official website for Soleno Therapeutics is http://www.soleno.life/.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]

MarketBeat Community Rating for Soleno Therapeutics (NASDAQ SLNO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  453
MarketBeat's community ratings are surveys of what our community members think about Soleno Therapeutics and other stocks. Vote "Outperform" if you believe SLNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel